Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs TransMedics Group Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $14.89 (market cap $7.07B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 2.3× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| NCLH | TMDX | |
|---|---|---|
Market Cap | $7.07B | $3.06B |
Sector | Consumer Cyclical | Technology |
52-Week High | $26.94 | $150.42 |
52-Week Low | $14.79 | $61.99 |
Enterprise Value | $21.88B | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $15.39, down 1.16% with bearish technical signals but attractive valuation metrics including a P/E of 9.33 and P/S of 0.74. The company has beaten earnings estimates for three consecutive quarters, though Q3 2026 faces a higher bar at $0.89 EPS. Recent news highlights fuel cost pressures from rising oil prices, contributing to the stock's recent decline despite positive operational developments like new waterpark openings and fleet expansion.
NCLH presents a value opportunity with strong profitability metrics (36.73% ROE) and analyst consensus price target of $20.25 (32% upside), but faces significant risks from fuel cost volatility, high leverage (debt-to-asset ratio 64.79%), and competitive pressure. The company's turnaround plan focusing on cost controls and fleet optimization must overcome macroeconomic headwinds to drive sustained recovery.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
